Impact BioMedical Balance Sheet Health
Financial Health criteria checks 0/6
Impact BioMedical has a total shareholder equity of $26.4M and total debt of $13.5M, which brings its debt-to-equity ratio to 51%. Its total assets and total liabilities are $44.1M and $17.7M respectively.
Key information
51.0%
Debt to equity ratio
US$13.45m
Debt
| Interest coverage ratio | n/a |
| Cash | US$2.00k |
| Equity | US$26.38m |
| Total liabilities | US$17.73m |
| Total assets | US$44.12m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: IBO's short term assets ($307.0K) do not cover its short term liabilities ($14.5M).
Long Term Liabilities: IBO's short term assets ($307.0K) do not cover its long term liabilities ($3.2M).
Debt to Equity History and Analysis
Debt Level: IBO's net debt to equity ratio (51%) is considered high.
Reducing Debt: IBO's debt to equity ratio has increased from 0% to 51% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IBO has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: IBO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 5.1% each year